
EquitySector - HealthcareVery High Risk
Regular
NAV (14-Nov-25)
Returns (Since Inception)
Fund Size
₹6,437 Cr
Expense Ratio
1.87%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.44%
+5.51% (Cat Avg.)
3 Years
+27.62%
+22.48% (Cat Avg.)
5 Years
+20.65%
+17.91% (Cat Avg.)
Since Inception
+21.07%
— (Cat Avg.)
| Equity | ₹6,250.44 Cr | 97.10% |
| Others | ₹186.92 Cr | 2.90% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹764.8 Cr | 11.88% |
| Dr Reddy's Laboratories Ltd | Equity | ₹606.54 Cr | 9.42% |
| Divi's Laboratories Ltd | Equity | ₹547.49 Cr | 8.50% |
| Aurobindo Pharma Ltd | Equity | ₹490.41 Cr | 7.62% |
| Cipla Ltd | Equity | ₹425.53 Cr | 6.61% |
| Lupin Ltd | Equity | ₹347.47 Cr | 5.40% |
| Alkem Laboratories Ltd | Equity | ₹256.14 Cr | 3.98% |
| Biocon Ltd | Equity | ₹211.36 Cr | 3.28% |
| Treps | Cash - Repurchase Agreement | ₹204.95 Cr | 3.18% |
| Mankind Pharma Ltd | Equity | ₹179.51 Cr | 2.79% |
| Zydus Lifesciences Ltd | Equity | ₹171.62 Cr | 2.67% |
| Syngene International Ltd | Equity | ₹143.42 Cr | 2.23% |
| Cohance Lifesciences Ltd | Equity | ₹134.2 Cr | 2.08% |
| Thyrocare Technologies Ltd | Equity | ₹130.62 Cr | 2.03% |
| Medi Assist Healthcare Services Ltd | Equity | ₹123.26 Cr | 1.91% |
| Alembic Pharmaceuticals Ltd | Equity | ₹113.91 Cr | 1.77% |
| Gland Pharma Ltd | Equity | ₹110.91 Cr | 1.72% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹97.36 Cr | 1.51% |
| Pfizer Ltd | Equity | ₹94.27 Cr | 1.46% |
| Metropolis Healthcare Ltd | Equity | ₹86.33 Cr | 1.34% |
| Windlas Biotech Ltd | Equity | ₹81.09 Cr | 1.26% |
| Medplus Health Services Ltd | Equity | ₹79.11 Cr | 1.23% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹75.61 Cr | 1.17% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹75.12 Cr | 1.17% |
| Anthem Biosciences Ltd | Equity | ₹74.75 Cr | 1.16% |
| Blue Jet Healthcare Ltd | Equity | ₹73.63 Cr | 1.14% |
| Aarti Drugs Ltd | Equity | ₹73.09 Cr | 1.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹71.64 Cr | 1.11% |
| Shilpa Medicare Ltd | Equity | ₹67.97 Cr | 1.06% |
| Emcure Pharmaceuticals Ltd | Equity | ₹58.78 Cr | 0.91% |
| FDC Ltd | Equity | ₹55.17 Cr | 0.86% |
| Hikal Ltd | Equity | ₹54.22 Cr | 0.84% |
| AstraZeneca Pharma India Ltd | Equity | ₹52.57 Cr | 0.82% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹51.17 Cr | 0.79% |
| Laxmi Dental Ltd | Equity | ₹50.51 Cr | 0.78% |
| Senores Pharmaceuticals Ltd | Equity | ₹49.42 Cr | 0.77% |
| Rubicon Research Ltd | Equity | ₹44.61 Cr | 0.69% |
| Procter & Gamble Health Ltd | Equity | ₹44.07 Cr | 0.68% |
| Sagility Ltd | Equity | ₹42.22 Cr | 0.66% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹40.5 Cr | 0.63% |
| Net Current Assets | Cash | ₹-26.44 Cr | 0.41% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
Large Cap Stocks
47.27%
Mid Cap Stocks
15.99%
Small Cap Stocks
31.98%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,099.71 Cr | 94.75% |
| Basic Materials | ₹75.61 Cr | 1.17% |
| Financial Services | ₹75.12 Cr | 1.17% |
Standard Deviation
This fund
15.69%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
1.20
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.87% | Exit Load 1.00% | Fund Size ₹6,437 Cr | Age 7 years 4 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹10,66,102 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (14-Nov-25)
Returns (Since Inception)
Fund Size
₹6,437 Cr
Expense Ratio
1.87%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.44%
+5.51% (Cat Avg.)
3 Years
+27.62%
+22.48% (Cat Avg.)
5 Years
+20.65%
+17.91% (Cat Avg.)
Since Inception
+21.07%
— (Cat Avg.)
| Equity | ₹6,250.44 Cr | 97.10% |
| Others | ₹186.92 Cr | 2.90% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹764.8 Cr | 11.88% |
| Dr Reddy's Laboratories Ltd | Equity | ₹606.54 Cr | 9.42% |
| Divi's Laboratories Ltd | Equity | ₹547.49 Cr | 8.50% |
| Aurobindo Pharma Ltd | Equity | ₹490.41 Cr | 7.62% |
| Cipla Ltd | Equity | ₹425.53 Cr | 6.61% |
| Lupin Ltd | Equity | ₹347.47 Cr | 5.40% |
| Alkem Laboratories Ltd | Equity | ₹256.14 Cr | 3.98% |
| Biocon Ltd | Equity | ₹211.36 Cr | 3.28% |
| Treps | Cash - Repurchase Agreement | ₹204.95 Cr | 3.18% |
| Mankind Pharma Ltd | Equity | ₹179.51 Cr | 2.79% |
| Zydus Lifesciences Ltd | Equity | ₹171.62 Cr | 2.67% |
| Syngene International Ltd | Equity | ₹143.42 Cr | 2.23% |
| Cohance Lifesciences Ltd | Equity | ₹134.2 Cr | 2.08% |
| Thyrocare Technologies Ltd | Equity | ₹130.62 Cr | 2.03% |
| Medi Assist Healthcare Services Ltd | Equity | ₹123.26 Cr | 1.91% |
| Alembic Pharmaceuticals Ltd | Equity | ₹113.91 Cr | 1.77% |
| Gland Pharma Ltd | Equity | ₹110.91 Cr | 1.72% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹97.36 Cr | 1.51% |
| Pfizer Ltd | Equity | ₹94.27 Cr | 1.46% |
| Metropolis Healthcare Ltd | Equity | ₹86.33 Cr | 1.34% |
| Windlas Biotech Ltd | Equity | ₹81.09 Cr | 1.26% |
| Medplus Health Services Ltd | Equity | ₹79.11 Cr | 1.23% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹75.61 Cr | 1.17% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹75.12 Cr | 1.17% |
| Anthem Biosciences Ltd | Equity | ₹74.75 Cr | 1.16% |
| Blue Jet Healthcare Ltd | Equity | ₹73.63 Cr | 1.14% |
| Aarti Drugs Ltd | Equity | ₹73.09 Cr | 1.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹71.64 Cr | 1.11% |
| Shilpa Medicare Ltd | Equity | ₹67.97 Cr | 1.06% |
| Emcure Pharmaceuticals Ltd | Equity | ₹58.78 Cr | 0.91% |
| FDC Ltd | Equity | ₹55.17 Cr | 0.86% |
| Hikal Ltd | Equity | ₹54.22 Cr | 0.84% |
| AstraZeneca Pharma India Ltd | Equity | ₹52.57 Cr | 0.82% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹51.17 Cr | 0.79% |
| Laxmi Dental Ltd | Equity | ₹50.51 Cr | 0.78% |
| Senores Pharmaceuticals Ltd | Equity | ₹49.42 Cr | 0.77% |
| Rubicon Research Ltd | Equity | ₹44.61 Cr | 0.69% |
| Procter & Gamble Health Ltd | Equity | ₹44.07 Cr | 0.68% |
| Sagility Ltd | Equity | ₹42.22 Cr | 0.66% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹40.5 Cr | 0.63% |
| Net Current Assets | Cash | ₹-26.44 Cr | 0.41% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
Large Cap Stocks
47.27%
Mid Cap Stocks
15.99%
Small Cap Stocks
31.98%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,099.71 Cr | 94.75% |
| Basic Materials | ₹75.61 Cr | 1.17% |
| Financial Services | ₹75.12 Cr | 1.17% |
Standard Deviation
This fund
15.69%
Cat. avg.
16.01%
Lower the better
Sharpe Ratio
This fund
1.20
Cat. avg.
0.93
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.67
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.87% | Exit Load 1.00% | Fund Size ₹6,437 Cr | Age 7 years 4 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹10,66,102 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments